Literature DB >> 12953133

Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.

T Saito1, Y Kanda, K Nakai, S-W Kim, F Arima, M Kami, R Tanosaki, K Tobinai, H Wakasugi, Y Heike, S Mineishi, Y Takaue.   

Abstract

The primary object of the conditioning regimen for allogeneic reduced-intensity stem cell transplantation (RIST) is immunosuppression to achieve stable engraftment of donor cells, rather than bone marrow ablation. Therefore, immune reconstitution after RIST might be different from that after conventional stem cell transplantation (CST). In this study, 22 patients underwent RIST and 28 underwent CST. The RIST regimen consisted of cladribine (2-CdA; 0.11 mg/kg/day for 6 days), BU (4 mg/kg/day for 2 days), and rabbit anti-thymocyte globulin (ATG; 2.5 mg/kg/day for 2-4 days). The CST group received either the BU (4 mg/kg/day x 4 days)/CY (60 mg/kg/day x 2 days) (n=13) or CY (60 mg/kg/day x 2 days)/TBI (4 Gy/day x 3 days) regimen (n=15). All patients underwent transplantation with G-CSF-mobilized blood stem cells. Engraftment speed after RIST was fast and seven of 22 patients did not require platelet transfusion. We noted that the numbers of CD4+, CD4+CD45RA+, and CD4+CD45RO+ T cells after transplant in the RIST group were significantly lower than those in the CST group (P=0.0001 for both the comparisons). However, the reconstitution of CD20+ B cells was faster in the RIST group (P=0.0001). The response of T cells to PHA stimulation was lower in the RIST group (P=0.0001 on day 30 and P=0.02 on day 90). Nevertheless, there were no significant differences in the incidence of bacterial, fungal, or viral infections between the two groups. We concluded that our RIST regimen might delay laboratory-evaluated T-cell immune reconstitution compared to CST; however, the observed setbacks did not directly translate into clinically significant increases in infectious episodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12953133     DOI: 10.1038/sj.bmt.1704205

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

2.  Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key.

Authors:  Haixia Fu; Lanping Xu; Daihong Liu; Xiaohui Zhang; Kaiyan Liu; Huan Chen; Yu Wang; Wei Han; Tingting Han; Xiaojun Huang
Journal:  Int J Hematol       Date:  2013-04-30       Impact factor: 2.490

3.  Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli.

Authors:  Hao Wei Li; Jessica Sachs; Clarimel Pichardo; Roderick Bronson; Guiling Zhao; Megan Sykes
Journal:  J Immunol       Date:  2012-11-07       Impact factor: 5.422

Review 4.  Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

5.  Tuberculosis before hematopoietic stem cell transplantation in patients with hematologic diseases: report of a single-center experience.

Authors:  K-S Eom; D-G Lee; H-J Lee; S-Y Cho; S-M Choi; J-K Choi; Y-J Kim; S Lee; H-J Kim; S-G Cho; J-W Lee
Journal:  Transpl Infect Dis       Date:  2015-01-12       Impact factor: 2.228

6.  Peri-transplant psychosocial factors and neutrophil recovery following hematopoietic stem cell transplantation.

Authors:  Jennifer M Knight; Jan A Moynihan; Jeffrey M Lyness; Yinglin Xia; Xin Tu; Susan Messing; Bryan C Hunter; Li-Shan Huang; Rosemary O Obi; D'Arcy Gaisser; Jane L Liesveld; Olle Jane Z Sahler
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.